Slade Eric P, Jahn Danielle R, Regenold William T, Case Brady G
Department of Psychiatry, University of Maryland School of Medicine, Baltimore2US Department of Veterans Affairs, Veterans Affairs Capitol Healthcare Network, Mental Illness Research, Education, and Clinical Center, Baltimore, Maryland.
Primary Care Institute, Gainesville, Florida.
JAMA Psychiatry. 2017 Aug 1;74(8):798-804. doi: 10.1001/jamapsychiatry.2017.1378.
Although electroconvulsive therapy (ECT) is considered the most efficacious treatment available for individuals with severe affective disorders, ECT's availability is limited and declining, suggesting that information about the population-level effects of ECT is needed.
To examine whether inpatient treatment with ECT is associated with a reduction in 30-day psychiatric readmission risk in a large, multistate sample of inpatients with severe affective disorders.
DESIGN, SETTING, AND PARTICIPANTS: A quasi-experimental instrumental variables probit model of the association correlation of ECT administration with patient risk of 30-day readmission was estimated using observational, longitudinal data on hospital inpatient discharges from US general hospitals in 9 states. From a population-based sample of 490 252 psychiatric inpatients, a sample was drawn that consisted of 162 691 individuals with a principal diagnosis of major depressive disorder (MDD), bipolar disorder, or schizoaffective disorder. The key instrumental variable used in the analysis was ECT prevalence in the prior calendar year at the treating hospital. To examine whether ECT's association with readmissions was heterogeneous across population subgroups, analyses included interactions of ECT with age group, sex, race/ethnicity, and diagnosis group. The study was conducted from August 27, 2015, to March 7, 2017.
Readmission within 30 days of being discharged.
Overall, 2486 of the 162 691 inpatients (1.5%) underwent ECT during their index admission. Compared with other inpatients, those who received ECT were older (mean [SD], 56.8 [16.5] vs 45.9 [16.5] years; P < .001) and more likely to be female (65.0% vs 54.2%; P < .001) and white non-Hispanic (85.3% vs 62.1%; P < .001), have MDD diagnoses (63.8% vs 32.0%; P < .001) rather than bipolar disorder (29.0% vs 40.0%; P < .001) or schizoaffective disorder (7.1% vs 28.0%; P < .001), have a comorbid medical condition (31.3% vs 26.6%; P < .001), have private (39.4% vs 21.7%; P < .001) or Medicare (49.2% vs 39.4%; P < .001) insurance coverage, and be located in urban small hospitals (31.2% vs 22.3%; P < .001) or nonurban hospitals (9.0% vs 7.6%; P = .02). Administration of ECT was associated with a reduced 30-day readmission risk among psychiatric inpatients with severe affective disorders from an estimated 12.3% among individuals not administered ECT to 6.6% among individuals administered ECT (risk ratio [RR], 0.54; 95% CI, 0.28-0.81). Significantly larger associations with ECT on readmission risk were found for men compared with women (RR, 0.44; 95% CI, 0.20-0.69 vs 0.58; 95% CI, 0.30-0.88) and for individuals with bipolar disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) compared with those who had MDD (RR, 0.53; 95% CI, 0.26-0.81).
Electroconvulsive therapy may be associated with reduced short-term psychiatric inpatient readmissions among psychiatric inpatients with severe affective disorders. This potential population health effect may be overlooked in US hospitals' current decision making regarding the availability of ECT.
尽管电休克治疗(ECT)被认为是治疗重度情感障碍患者最有效的方法,但ECT的可及性有限且呈下降趋势,这表明需要了解ECT对人群层面的影响信息。
在一个来自多个州的大型重度情感障碍住院患者样本中,研究住院期间接受ECT治疗是否与30天内精神科再入院风险降低相关。
设计、背景和参与者:使用来自9个州美国综合医院住院患者出院情况的观察性纵向数据,估计了ECT治疗与患者30天再入院风险之间关联的准实验性工具变量概率模型。从490252名精神科住院患者的人群样本中,抽取了一个由162691名主要诊断为重度抑郁症(MDD)、双相情感障碍或精神分裂症的个体组成的样本。分析中使用的关键工具变量是治疗医院前一个日历年的ECT普及率。为了检验ECT与再入院之间的关联在不同人群亚组中是否存在异质性,分析包括ECT与年龄组、性别、种族/族裔和诊断组的交互作用。该研究于2015年8月27日至2017年3月7日进行。
出院后30天内再入院。
总体而言,162691名住院患者中有2486名(1.5%)在其首次住院期间接受了ECT治疗。与其他住院患者相比,接受ECT治疗的患者年龄更大(平均[标准差],56.8[16.5]岁对45.9[16.5]岁;P<.001),更可能为女性(65.0%对54.2%;P<.001)和非西班牙裔白人(85.3%对62.1%;P<.001),患有MDD诊断(63.8%对32.0%;P<.001)而非双相情感障碍(29.0%对40.0%;P<.001)或精神分裂症(7.1%对28.0%;P<.001),有合并内科疾病(31.3%对26.6%;P<.001),有私人保险(39.4%对21.7%;P<.001)或医疗保险(49.2%对39.4%;P<.001),且位于城市小型医院(31.2%对22.3%;P<.001)或非城市医院(9.0%对7.6%;P=.02)。ECT治疗与重度情感障碍精神科住院患者30天再入院风险降低相关,从未接受ECT治疗患者的估计12.3%降至接受ECT治疗患者的6.6%(风险比[RR],0.54;95%置信区间,0.28 - 0.81)。与女性相比,男性ECT治疗与再入院风险的关联显著更大(RR,0.44;95%置信区间,0.20 - 0.69对0.58;95%置信区间,0.30 - 0.88),与患有MDD的患者相比,双相情感障碍(RR,0.42;95%置信区间,0.17 - 0.69)和精神分裂症(RR,0.44;95%置信区间,0.11 - 0.79)患者ECT治疗与再入院风险的关联更大。
电休克治疗可能与重度情感障碍精神科住院患者短期精神科再入院率降低相关。在美国医院目前关于ECT可及性的决策中,这种潜在的人群健康效应可能被忽视。